Female Hypoactive Sexual Desire Disorder Therapeutics Market Scope And Analysis

  • Report Code : TIPRE00010487
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Female Hypoactive Sexual Desire Disorder Therapeutics Market Analysis and Scope (2025 to 2031)

Buy Now

Female Hypoactive Sexual Desire Disorder Therapeutics Market Report Scope

Report Attribute Details
Market size in 2024 US$ XX million
Market Size by 2031 US$ XX Million
Global CAGR (2025 - 2031) XX%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Therapy
  • Testosterone
  • Flibanserin
  • Buspirone
  • Bupropion
  • Bremelanotide
  • Cognitive Behavior Therapy
By Application
  • In-patient
  • Out-patient
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Allergan plc
  • AMAG Pharmaceuticals Inc
  • Emotional Brain BV
  • Endoceutics Inc
  • GlaxoSmithKline Plc
  • Merck Co Inc
  • Palatin Technologies Inc
  • Pivot Pharmaceuticals Inc
  • Sprout Pharmaceuticals Inc